Last year, Greiner Bio-One employed a worldwide workforce of 2,320 at 28 locations in 20 countries, hitting sales revenues of EUR 509 million, which represented growth of 8% over 2018 (EUR 473 million), passing the EUR 500 million mark for the first time.
Therefore, in spite of a challenging market environment, the successful business trend of recent years was maintained. Moreover, extensive increases in capacity enabled the use of a range of fresh potential and new customers were also obtained. In particular, market shares were gained in the USA and Latin America and positive currency effects emanating from the exchange rates for the US dollar and Japanese yen generated additional momentum. The global production and distribution network ensures that customers are quickly supplied locally. The business result also benefited from the fall in raw material prices, which was particularly notable in the second half-year.
Asia is an important growth market
In 2019, measures aimed at further strengthening the market presence in Asia were again implemented. With a population of over 260 million and a rapidly growing economy, Indonesia is one of Southeast Asia’s most important growth markets. Therefore, in February Greiner Bio-One opened a representative office in Jakarta, the nation’s capital, and has thus moved closer to its customers with the aim of responding to their requirements to an even better degree in future.
The production plant in Thailand plays a major role in the successful supply of the Asian market. However, owing to the continual growth of recent years, its spatial capacity is exhausted. Consequently, in June 2019 work commenced on the enlargement of the Thai location’s production and storage facilities, which will be completed in 2020.
The Frickenhausen location (Germany) is also of great importance to international supplies and as part of a large-scale infrastructure project, in 2019 construction work began on extensions to both the production and administrative buildings, which will be finished in 2020.
Greiner Bio-One looks to the 2020 financial year with confidence. The current corona pandemic holds both opportunities and risks for the company. Although there is a lower demand for some products due to a decline in routine examinations in hospitals or closed universities and laboratories, other products are being used more frequently. As one of the supporting companies in maintaining the health care system, Greiner Bio-One products are needed, for example, in vaccine and test development and in acute SARS-CoV-2 diagnostics.
For more information, please fill out the enquiry form attached to this page.
Greiner Bio-One is launching a new product as part of its VACUETTE® line – the...
Ever since the alarming news about the global Covid-19 pandemic and the far-reaching effects, the...
We are pleased to announce the release of the fourth edition of our client magazine...